Literature DB >> 9547991

Epstein-Barr virus infection and the pathogenesis of malignant lymphomas.

G Niedobitek1, L S Young, H Herbst.   

Abstract

EBV is associated with an ever increasing number of human malignancies, which illustrates the importance of understanding how the virus contributes to tumorigenesis. Recent work has identified as set of EBV latent proteins that are indispensable for B cell transformation in vitro, and possible mechanisms of action are beginning to emerge for some of these proteins. In addition to viral gene expression, host factors appear to be involved in the development of virus associated tumours. Firstly, virus specific immunity is important for preventing the outgrowth of EBV associated tumours. Disturbances of EBV specific immunosurveillance can occur as a consequence of systemic immunosuppression or due to local factors, some of which may directly or indirectly result from the expression of EBV genes. Secondly, the phenotype of virus infected cells seems to be important. Thus, many EBV associated tumours appear to arise from cell types that do not represent a "physiological" target for the virus and thus may not be adapted to establishing asymptomatic persistent EBV infection. Furthermore, the function of transformation associated viral gene products may vary according to the cellular phenotype.

Entities:  

Mesh:

Year:  1997        PMID: 9547991

Source DB:  PubMed          Journal:  Cancer Surv        ISSN: 0261-2429


  9 in total

1.  LMP1 signal transduction differs substantially from TNF receptor 1 signaling in the molecular functions of TRADD and TRAF2.

Authors:  A Kieser; C Kaiser; W Hammerschmidt
Journal:  EMBO J       Date:  1999-05-04       Impact factor: 11.598

2.  Perinatal and family risk factors for non-Hodgkin lymphoma in early life: a Swedish national cohort study.

Authors:  Casey Crump; Kristina Sundquist; Weiva Sieh; Marilyn A Winkleby; Jan Sundquist
Journal:  J Natl Cancer Inst       Date:  2012-05-22       Impact factor: 13.506

3.  Season of birth and risk of Hodgkin and non-Hodgkin lymphoma.

Authors:  Casey Crump; Jan Sundquist; Weiva Sieh; Marilyn A Winkleby; Kristina Sundquist
Journal:  Int J Cancer       Date:  2014-04-25       Impact factor: 7.396

Review 4.  Hodgkin's lymphoma: the pathologist's viewpoint.

Authors:  S A Pileri; S Ascani; L Leoncini; E Sabattini; P L Zinzani; P P Piccaluga; A Pileri; M Giunti; B Falini; G B Bolis; H Stein
Journal:  J Clin Pathol       Date:  2002-03       Impact factor: 3.411

5.  EBV-associated post-transplantation B-cell lymphoproliferative disorder following allogenic stem cell transplantation for acute lymphoblastic leukaemia: tumor regression after reduction of immunosuppression--a case report.

Authors:  Alexander Krenauer; Alexander Moll; Wolfram Pönisch; Nicole Schmitz; Gerald Niedobitek; Dietger Niederwieser; Thomas Aigner
Journal:  Diagn Pathol       Date:  2010-03-31       Impact factor: 2.644

6.  Pathobiology of hodgkin lymphoma.

Authors:  Pier Paolo Piccaluga; Claudio Agostinelli; Anna Gazzola; Claudio Tripodo; Francesco Bacci; Elena Sabattini; Maria Teresa Sista; Claudia Mannu; Maria Rosaria Sapienza; Maura Rossi; Maria Antonella Laginestra; Carlo A Sagramoso-Sacchetti; Simona Righi; Stefano A Pileri
Journal:  Adv Hematol       Date:  2010-12-22

7.  Epstein- Barr Virus: Clinical and Epidemiological Revisits and Genetic Basis of Oncogenesis.

Authors:  Abdelwahid Saeed Ali; Mubarak Al-Shraim; Ahmed Musa Al-Hakami; Ian M Jones
Journal:  Open Virol J       Date:  2015-11-03

8.  Characterization of the subcellular localization of Epstein-Barr virus encoded proteins in live cells.

Authors:  Mingsheng Cai; Zongmin Liao; Tao Chen; Ping Wang; Xingmei Zou; Yuanfang Wang; Zuo Xu; Si Jiang; Jinlu Huang; Daixiong Chen; Tao Peng; Gengde Hong; Meili Li
Journal:  Oncotarget       Date:  2017-07-25

Review 9.  Mechanistic Insights into Chemoresistance Mediated by Oncogenic Viruses in Lymphomas.

Authors:  Jungang Chen; Samantha Kendrick; Zhiqiang Qin
Journal:  Viruses       Date:  2019-12-16       Impact factor: 5.048

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.